Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BioMarin's Cerliponase Alfa Data Support Mid-Year Submissions

This article was originally published in Scrip

Executive Summary

BioMarin Pharmaceutical Inc.'s cerliponase alfa (BMN 190) significantly slowed the rate of neurodegenerative decline for young patients with CLN2, a form of Batten disease, compared with historical controls in a Phase I/II clinical trial, supporting plans to seek US and EU regulatory approvals within the next few months.


Related Content

10 Approvals To Watch For In Early 2017
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago